2018 Neurotech Leaders Forum

October 15-16, 2018

Embassy Suites, San Francisco Airport Waterfront

Tentative Agenda

Day One

8:00-8:30

Registration and Coffee

8:30-9:15

State of the Neurotechnology Industry: 2018

James Cavuoto, Editor and Publisher, Neurotech Reports
Neurotech Business Report Editor James Cavuoto provides his insights and observations on the state of the neurotechnology industry. He surveys changes in the competitive landscape that have occured over the years, the most significant events of the last year, and challenges confronting the industry in years ahead.
9:15-10:00

Keynote Address

Frank Fischer, CEO, NeuroPace Inc.
10:00-10:30

Refreshment Break

10:30-11:15

Preparing for Exit: Neurotech Funding Alternatives

Jennifer French, Senior Editor, Neurotech Reports, Moderator
Doug Clinton, Managing Partner, Loup Ventures
Mark Lindon, General Counsel and Chairman, Bioness Inc.
Ajay Khatri, Director of Equity Investments, Johnson & Johnson Development Corp.
Manuel López-Figueroa, Vice-President, Bay City Capital
Neurotech startups have access to a variety of equity and non-dilutive financing options. In this panel, we'll address some of the key decisions that entrepreneurs must confront when planning their long-term strategy.
11:15-12:00

Sharing the Pain: What the Opioid Crisis Means for Neuromodulation

James Cavuoto, Editor, Neurotech Reports, Moderator
Stephanie Fertig, SBIR Project Manager, NIH/NINDS
Prasad Shirvalkar M.D., Ph.D., Assistant Clinical Professor, UC San Francisco
Michael Leong, M.D., Clinical Associate Professor, Stanford Pain Center
The opioid crisis has created new opportunitites for pain neuromodulation device vendors, and the U.S. government has just set aside $500 million to address the problem. In this session, we'll discuss how the industry can best serve the healthcare system and how to handle the hurdles still facing suppliers of non-pharmaceutical therapies.
12:00-1:30

Luncheon, Sponsored by Cirtec Medical

Brian Highley, CEO, Cirtec Medical
1:30-3:00

Neurotechnology Entrepreneur Panel

James Cavuoto, Editor, Neurotech Reports, Moderator
Manfred Franke, Ph.D., Founder & CEO, NeurOnOff, Inc.
Bill Edelman, Chairman, Highland Instruments Inc.
Pawel Soluch, CEO, Neuro Device Group, S.A.
Isaac Clements, Ph.D., Vice President, R&D, BioCircuit Technologies
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets.
3:00-3:30

Refreshment Break

3:30-4:15

Probing the Lead: Advances in Neural Interface Technology

Jennifer French, Senior Editor, Neurotech Reports, Moderator
Dries Braeken, Ph.D., R&D Manager, IMEC Life Science Technologies
Andrew Kelly, IC/Systems Architect, Cactus Semiconductor
Nick Halper, Product Manager, Neural Interfaces, Blackrock Microsystems
Neural engineers have made considerable progress in designing new electrodes, probes, leads, and interconnects used in implanted neurotech devices. In this session, we'll look at at recent innovations in materials, components, and manufacturing methods.
4:15-5:00

Paying the Piper: New Directions in Pricing and Reimbursement

Jeremy Koff, Senior Contributing Editor, Neurotech Reports, Moderator
Tom Hughes, Sr. Principal Advisor, Regulatory & Clinical Research Institute, Inc.
Courtney Lane, Principal, Anacapa Clinical Research
Several pioneering neurotechnology firms have introduced new pricing and revenue models that could fundamentally alter the way neurotech devices are financed. In this session, we'll discuss examples of per-dose neuromodulation pricing, as well as novel strategies for obtaining reimbursement from private and government payers.
5:00-7:00

Cocktail Reception, Sponsored by MST

 
 

 

Day Two

8:00:8:30

Registration and Coffee

8:30-8:45

Standing Out from the Crowd: Neuromodulation Gets Competitive

James Cavuoto, Editor and Publisher, Neurotech Reports
Neurotech Reports editor James Cavuoto provides his insight on the new competitive landscape within the neuromodulation industry. He'll provide an overview of the players battling for market share in markets like SCS, DBS, SNS, TMS, neuroprosthetics, neurorobotics, and others.
8:45-9:15

Keynote Address

P. Hunter Peckham, Ph.D., Founder, Institute for Functional Restoration
9:15-10:00

Regulatory Update: The U.S. vs. Overseas

James Cavuoto, Editor and Publisher, Neurotech Reports, Moderator
Cristin Welle, Ph.D., Assistant Professor, University of Colorado, Denver
Nick Langhals, Ph.D., Neural Engineering Program Manager, NIH NINDS
Victor Pikov, Ph.D., CEO, Medipace, Inc.
Regulatory changes in Europe and other regions may swing the pendulum back toward the U.S. in terms of getting new neurotech products to market. In this session, we'll look at recent trends in FDA approval of new devices vis a vis in international markets.
10:00-10:30

Coffee Break

10:30-11:15

Fixing Brain and Body: Advances in Neurorehabilitation and Cortical Stimulation

Jennifer French, Senior Editor, Neurotech Reports, Moderator
Bashar Badran, Ph.D., Research Assistant Professor, UNM and U.S. Army Research Laboratories
Evan L. Rosenfeld, M.D., Principal, MD|JD Consulting
Jose Antonio Tovar, Clinical Applications Manager, Hocoma AG
Brain stimulation--both noninvasive and implanted--has become a powerful tool for fostering recovery from neurological disorders such as stroke, TBI, and others. In this session, we'll look at several examples of promising therapies for both neuromuscular and cognitive disorders.
11:15-12:00

Going Bioelectronic: The Coming Merger of Neuromodulation and Bioelectronic Medicine

James Cavuoto, Editor and Publisher, Neurotech Reports, Moderator
Anthony Arnold, Consultant, SetPoint Medical
Michael Ackermann, Ph.D., CEO, Presidio Medical Inc.
Chris Czura, Ph.D., Vice President, Feinstein Institute for Medical Research
As the new field of bioelectronic medicine has emerged, it has raised questions about where it fits within the neuromodulation industry. In this session, we'll explore the boundaries of both fields and discuss the opportunities for recruiting staff, technology, and infrastructure from the biopharmaceutical industry.
12:00-1:30

Luncheon, Sponsored by Cirtec Medical

Presentation of 2018 Gold Electrode Awards
1:30-3:00

Neurotechnology Entrepreneur Panel

James Cavuoto, Editor, Neurotech Reports, Moderator
Howard Leonhardt, CEO, CerebraCell
Blake Gurfein, Ph.D., V.P. of Reaearch & Scientific Affairs, Tivic Health
Megan Moynahan, Executive Director, Institute for Functional Restoration
Naharika Gajawelli, Ph.D., COO, Voxel Healthcare
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets.
3:00-3:30

Refreshment Break

3:30-4:15

Neurotech's Farm System: Nurturing the Next Generation of Devices and Therapies

Joe Bird, Shareholder, Maynard Cooper, Moderator
Edward Chang, M.D., Co-Director, Center for Neural Engineering at UC Berkeley and SF
Claude Clement, Chief Technology Officer, Wyss Center for Bio and Neuroengineering
Andrew Cornell, Ph.D., Associate Director, Case Coulter Translational Research Partnership
Most of the neurotechnology products on the market today began life in a university or private research laboratory. In this session, we'll look at some of the leading neurotechnology research institutions and examine the role that technology transfer offices can play in commercializing new products.
4:15-5:00

Brain Barriers: Exploring the Limits of Brain Stimulation and Sensing

James Cavuoto, Editor, Neurotech Reports, Moderator
Philip Starr, Ph.D., M.D., Professor of Neurological Surgery, UC San Francisco
Dan Rizzuto, Ph.D., CEO, Nia Therapeutics
John Donoghue, Ph.D., Director, Wyss Center for Bio and Neuroengineering
Advances in technologies such as deep-brain-stimuation, EEG sensing, and brain-computer interfaces have made possible a new generation of clinical and consumer products. In this closing session, we'll explore the technological and ethical boundaries of brain interfacing. And we'll debate what limits should be placed on product development and distribution.
5:00-7:00

Cocktail Reception, Sponsored by MST

 
 

 

site design by shalatdesign | shalat.com